US 11,737,974 B2
SARS-CoV-2 subunit vaccine and microneedle array delivery system
Andrea Gambotto, Pittsburgh, PA (US); Louis Falo, Jr., Wexford, PA (US); and Eun Kim, Allison Park, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Nov. 30, 2021, as Appl. No. 17/538,412.
Application 17/538,412 is a continuation of application No. 17/009,121, filed on Sep. 1, 2020, granted, now 11,213,482.
Claims priority of provisional application 62/989,208, filed on Mar. 13, 2020.
Claims priority of provisional application 62/985,498, filed on Mar. 5, 2020.
Prior Publication US 2022/0087930 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 9/00 (2006.01); A61K 47/58 (2017.01); A61B 5/15 (2006.01); A61K 39/39 (2006.01)
CPC A61K 9/0021 (2013.01) [A61B 5/150984 (2013.01); A61K 39/39 (2013.01); A61K 47/58 (2017.08); A61K 2039/505 (2013.01)] 7 Claims
 
1. A method of vaccinating a patient for SARS-CoV-2, comprising administering to the patient an amount of a composition, by a route of administration effective to induce an immune response to SARS-CoV-2, wherein said composition comprises (a) a fusion polypeptide comprising (i) an immunogenic amino acid sequence of a SARS-CoV-2 spike protein and (ii) a Toll-like receptor agonist domain, and (b) a pharmaceutically acceptable excipient, wherein said Toll-like receptor agonist domain is a polypeptide.